Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group

Moulopoulos, L.A. (Lia A.); Koutoulidis, V. (Vassilis); Hillengass, J. (Jens); Zamagni, E. (Elena); Aquerreta, J.D. (Jesús D.); Roche, C.L. (Charles L.); Lentzsch, S. (Suzanne); Moreau, P. (Philippe); Cavo, M. (Michele); San-Miguel, J.F. (Jesús F.); Dimopoulos, M.A. (Meletios A.); Rajkumar, S.V. (S. Vincent); Durie, B. (B.); Terpos, E. (Evangelos); Delorme, S. (Stefan)

Palabras clave :

Whole body low dose CT (WBLDCT)
First-line imaging modality

Fecha de publicación :

2018

Editorial :

Springer Nature

ISSN :

2044-5385

Nota:

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder

Cita:

Moulopoulos, L.A. (Lia A.); Koutoulidis, V. (Vassilis); Hillengass, J. (Jens); et al. "Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group". Blood cancer journal. 8 (95), 2018,

Resumen

Whole Body Low Dose CT (WBLDCT) has important advantages as a first-line imaging modality for bone disease assessment in patients with plasma cell disorders and has been included in the 2014 International Myeloma Working Group (IMWG) criteria for multiple myeloma (MM) definition. Nevertheless, standardization guidelines for the optimal use of WBLDCT in MM patients are still lacking, preventing its more widespread use, both in daily practice and clinical trials. The aim of this report by the Bone Group of the IMWG is to provide practical recommendations for the acquisition, interpretation and reporting of WBLDCT in patients with multiple myeloma and other plasma cell disorders.

URI :

https://hdl.handle.net/10171/64745

DOI:

10.1038/s41408-018-0124-1

Aparece en las colecciones:

DA - CUN - Hematología y Hemoterapia - Artículos de revista
DA - CUN - Radiología - Artículos de revista

Ficheros en este ítem: